About elosulfase alfa
Enzyme replacement therapy
Used for
- Long-term treatment of mucopolysaccharidosis type IVA (Morquio A syndrome).
Usual adult dose
2 mg/kg by intravenous infusion once weekly.
Usual dose in children
2 mg/kg by intravenous infusion once weekly; used in children from 5 years old.
Common side effects
- Infusion reactions, including fever, chills, rash, or breathing difficulties
- Vomiting, nausea, or abdominal pain
- Headache or dizziness
- Serious allergic reactions, including anaphylaxis
Important warnings
- Infusions require monitoring because severe allergic reactions can occur.
- Breathing problems may worsen during infusion, especially with sleep apnoea.
- Antihistamines, with or without fever-reducing medicines, are given before infusion.
- Treatment should be supervised by a healthcare professional experienced in Morquio A syndrome.
Pregnancy
There is limited information in pregnancy; use only when a clinician considers treatment necessary.
Breastfeeding
It is not known whether elosulfase alfa passes into breast milk; discuss treatment with a clinician.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.